Health Canada Approves Updated Protocol for Redsenol-1 Plus Clinical Trial
News related to:Canada Royal Enoch Phytomedicine Ltd · 2 min read
RICHMOND, BC, September 10, 2026 /CourierPR/ -- Health Canada has given the green light to an updated clinical trial protocol for Redsenol-1 Plus Noble Ginsenoside Capsules, an investigational natural health product developed by Canada Royal Enoch Phytomedicine Ltd. The revised protocol will allow the study to continue under a new framework, with the primary aim of exploring the potential of Redsenol-1 Plus in managing cancer-related fatigue (CRF).
Cancer-related fatigue is a significant challenge for many patients undergoing or recovering from anticancer treatments such as chemotherapy and radiotherapy. The clinical trial, which has been ongoing since 2022, aims to gather more data on the effectiveness of Redsenol-1 Plus in alleviating this debilitating condition. Redsenol-1 Plus is an oral botanical formulation containing sixteen rare ginsenosides derived from ginseng, including Rg3 (R, S), Rh1 (S, R), Rh2 (R, S), Rk1, Rk3, Rg5, Rh3, Rh4, Rk2, aPPD (S, R), and aPPT (S, R). This unique blend of ginsenosides is marketed as a potential support for cancer patients’ quality of life.
Dr. Peihua Yu, CEO of Canada Royal Enoch Phytomedicine, highlighted the importance of addressing CRF, stating, “Cancer-related fatigue is a long-term challenge faced by many patients, yet it is often overlooked. Since the study began, we have continued to advance the clinical trial and learn from practical experience gained throughout the research process.”
The updated clinical trial protocol will allow for more eligible cancer patients to participate, potentially providing them with access to the investigational natural health product. The study is registered on ClinicalTrials.gov under the identifier NCT05664009.
Canada Royal Enoch Phytomedicine is a biotechnology company specializing in the research, production, and sales of natural plant-based health products. The company’s flagship brand, Redsenol, is a ginsenoside supplement featuring multicomponent rare ginsenosides in high concentrations. Through its proprietary technologies in rare ginsenoside extraction, processing, transformation, and formulation, Canada Royal Enoch Phytomedicine aims to unlock the full potential of ginseng and ginsenosides for health and wellness.
The company’s commitment to advancing research in natural health products for cancer supportive care is evident in the ongoing clinical trial. As the trial progresses, the results could contribute valuable insights into the role of natural health products in managing the side effects of cancer treatment. This development marks a significant step in the company’s efforts to provide innovative solutions for improving the quality of life for cancer patients.
The study’s updated framework will enable researchers to refine the study design and participant access based on practical experience gained during the clinical trial. With Health Canada’s no-objection notification, the research team can continue to advance the clinical trial and potentially bring Redsenol-1 Plus to market as a supportive care option for cancer patients experiencing CRF.